JP2023133525A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2023133525A5 JP2023133525A5 JP2023126665A JP2023126665A JP2023133525A5 JP 2023133525 A5 JP2023133525 A5 JP 2023133525A5 JP 2023126665 A JP2023126665 A JP 2023126665A JP 2023126665 A JP2023126665 A JP 2023126665A JP 2023133525 A5 JP2023133525 A5 JP 2023133525A5
- Authority
- JP
- Japan
- Prior art keywords
- day
- cancer
- antibody
- medicament according
- severity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461936168P | 2014-02-05 | 2014-02-05 | |
| US61/936,168 | 2014-02-05 | ||
| JP2016550261A JP2017507931A (ja) | 2014-02-05 | 2015-02-05 | がん及び感染症の治療方法並びに治療用組成物 |
| JP2020144077A JP7328187B2 (ja) | 2014-02-05 | 2020-08-28 | がん及び感染症の治療方法並びに治療用組成物 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020144077A Division JP7328187B2 (ja) | 2014-02-05 | 2020-08-28 | がん及び感染症の治療方法並びに治療用組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023133525A JP2023133525A (ja) | 2023-09-22 |
| JP2023133525A5 true JP2023133525A5 (enExample) | 2023-12-04 |
| JP7767361B2 JP7767361B2 (ja) | 2025-11-11 |
Family
ID=53778458
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016550261A Pending JP2017507931A (ja) | 2014-02-05 | 2015-02-05 | がん及び感染症の治療方法並びに治療用組成物 |
| JP2020144077A Active JP7328187B2 (ja) | 2014-02-05 | 2020-08-28 | がん及び感染症の治療方法並びに治療用組成物 |
| JP2023126665A Active JP7767361B2 (ja) | 2014-02-05 | 2023-08-03 | がん及び感染症の治療方法並びに治療用組成物 |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016550261A Pending JP2017507931A (ja) | 2014-02-05 | 2015-02-05 | がん及び感染症の治療方法並びに治療用組成物 |
| JP2020144077A Active JP7328187B2 (ja) | 2014-02-05 | 2020-08-28 | がん及び感染症の治療方法並びに治療用組成物 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US11213583B2 (enExample) |
| EP (1) | EP3102233B1 (enExample) |
| JP (3) | JP2017507931A (enExample) |
| CN (1) | CN105979961B (enExample) |
| CA (1) | CA2937035A1 (enExample) |
| WO (1) | WO2015120198A1 (enExample) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI729512B (zh) | 2008-12-09 | 2021-06-01 | 美商建南德克公司 | 抗pd-l1抗體及其於增進t細胞功能之用途 |
| US8906374B2 (en) | 2010-04-20 | 2014-12-09 | Cedars-Sinai Medical Center | Combination therapy with CD4 lymphocyte depletion and mTOR inhibitors |
| US10570204B2 (en) | 2013-09-26 | 2020-02-25 | The Medical College Of Wisconsin, Inc. | Methods for treating hematologic cancers |
| JOP20200094A1 (ar) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
| JOP20200096A1 (ar) | 2014-01-31 | 2017-06-16 | Children’S Medical Center Corp | جزيئات جسم مضاد لـ tim-3 واستخداماتها |
| CN105979961B (zh) * | 2014-02-05 | 2020-12-18 | 西达-赛奈医疗中心 | 用于治疗癌症和感染性疾病的方法和组合物 |
| US20170165364A1 (en) * | 2014-02-21 | 2017-06-15 | Idac Theranostics, Inc. | Therapeutic agent for solid cancer |
| EP3660050A1 (en) | 2014-03-14 | 2020-06-03 | Novartis AG | Antibody molecules to lag-3 and uses thereof |
| MX2016012779A (es) | 2014-03-31 | 2017-04-27 | Genentech Inc | Terapia de combinacion con agentes antiangiogénesis y agonistas de unión a ox40. |
| EP3156072B1 (en) * | 2014-06-11 | 2020-08-19 | IDAC Theranostics, Inc. | Method for reducing side effects of immune checkpoint control agent |
| KR20170060042A (ko) | 2014-09-13 | 2017-05-31 | 노파르티스 아게 | Alk 억제제의 조합 요법 |
| CN114920840A (zh) | 2014-10-14 | 2022-08-19 | 诺华股份有限公司 | 针对pd-l1的抗体分子及其用途 |
| WO2016090219A1 (en) * | 2014-12-05 | 2016-06-09 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Bromodomain inhibitor as adjuvant in cancer immunotherapy |
| EP3310384A1 (en) * | 2015-06-17 | 2018-04-25 | CureVac AG | Vaccine composition |
| EP3337514B8 (en) | 2015-08-18 | 2022-04-06 | Rakuten Medical, Inc. | Composition comprising a conjugate comprising a phthalocyanine dye linked to a targeting molecule for photoimmunotherapy |
| CN108136215B (zh) | 2015-08-18 | 2022-04-29 | 乐天医药生技股份有限公司 | 酞菁染料偶联物的制造方法及稳定偶联物 |
| MA43017A (fr) | 2015-10-02 | 2018-08-08 | Hoffmann La Roche | Anticorps bispécifiques spécifiques d'un récepteur de co-stimulation du tnf |
| TWI895621B (zh) | 2016-05-27 | 2025-09-01 | 美商艾吉納斯公司 | 抗-tim-3抗體及其使用方法 |
| EP3494139B1 (en) | 2016-08-05 | 2022-01-12 | F. Hoffmann-La Roche AG | Multivalent and multiepitopic anitibodies having agonistic activity and methods of use |
| WO2018031507A1 (en) * | 2016-08-09 | 2018-02-15 | Angimmune, Llc | Treatment of cancer using a combination of immunomodulation and check point inhibitors |
| KR102576042B1 (ko) | 2016-10-11 | 2023-09-07 | 아게누스 인코포레이티드 | 항-lag-3 항체 및 이의 사용 방법 |
| JP7384669B2 (ja) * | 2017-10-30 | 2023-11-21 | Ｕｂｅ株式会社 | 置換ジヒドロピロロピラゾール化合物および免疫療法剤が組み合わせて投与される医薬組成物 |
| KR102721494B1 (ko) * | 2018-04-17 | 2024-10-24 | 국립암센터 | 고갈성 항 cd4 단일클론항체를 포함하는 항암 t 세포치료제 보조용 조성물 및 이의 용도 |
| EA202190862A1 (ru) * | 2018-09-27 | 2021-07-07 | Геноцеа Байосайенсиз, Инк. | Способы лечения |
| KR102300846B1 (ko) * | 2019-11-01 | 2021-09-09 | 서울대학교산학협력단 | 면역 활성 개선용 조성물 및 이의 방법 |
| KR20220114556A (ko) * | 2019-11-18 | 2022-08-17 | 칠드런'즈 메디컬 센터 코포레이션 | 암 면역요법을 위한 상주 수지상 세포를 과다활성화시키는 자극제 |
| CN115916837A (zh) * | 2020-01-30 | 2023-04-04 | 阿昔单抗治疗有限公司 | 用pla2g2d拮抗剂治疗癌症或病毒感染的方法和组合物 |
| CN115197320A (zh) | 2021-04-07 | 2022-10-18 | 中美冠科生物技术（太仓）有限公司 | 新型抗cd4抗体 |
| IL322401A (en) * | 2023-02-06 | 2025-09-01 | Gmp Biotechnology Ltd | MTOR therapies for cancer |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1292686C (en) | 1986-10-27 | 1991-12-03 | Ze'ev Shaked | Pharmaceutical compositions of recombinant interleukin-2 and formulation process |
| CA1294215C (en) | 1986-10-27 | 1992-01-14 | Ze'ev Shaked | Pharmaceutical compositions of recombinant beta-interferon and formulation processes |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US6136310A (en) | 1991-07-25 | 2000-10-24 | Idec Pharmaceuticals Corporation | Recombinant anti-CD4 antibodies for human therapy |
| GB2302353B (en) | 1995-06-21 | 1998-11-11 | British Gas Plc | Method of filling an excavated opening |
| GB0217777D0 (en) | 2002-07-31 | 2002-09-11 | Novartis Ag | Organic compounds |
| BRPI0316282B8 (pt) | 2002-11-15 | 2021-05-25 | Genmab As | anticorpo humano isolado monoclonal, composição, imunoconjugado, molécula biespecífica ou multiespecífica, método e conjunto de diagnóstico para detectar a presença de antígeno cd25 ou uma célula que expressa cd25, e, vetor de expressão |
| EP2366717A3 (en) | 2004-10-29 | 2011-12-14 | University of Southern California | Combination Cancer Immunotherapy with Co-Stimulatory Molecules |
| US20090317407A1 (en) * | 2006-05-02 | 2009-12-24 | Lacelle Michael G | Augmentation of immune response to cancer vaccine |
| JP2009539769A (ja) | 2006-06-02 | 2009-11-19 | アリアド ジーン セラピューティクス インコーポレイテッド | カペシタビン併用療法 |
| CN101472611A (zh) | 2006-06-19 | 2009-07-01 | 惠氏公司 | 调节il-22和il-17的方法 |
| JP5399900B2 (ja) | 2006-06-30 | 2014-01-29 | メルク・シャープ・アンド・ドーム・コーポレーション | Ｉｇｆｂｐ２インヒビター |
| EA023148B1 (ru) * | 2008-08-25 | 2016-04-29 | Эмплиммьюн, Инк. | Композиции на основе антагонистов pd-1 и их применение |
| WO2010074266A1 (ja) * | 2008-12-26 | 2010-07-01 | 協和発酵キリン株式会社 | 抗cd4抗体 |
| WO2010083298A1 (en) | 2009-01-14 | 2010-07-22 | Health Research Inc. | Methods and compositions containing mtor inhibitors for enhancing immune responses |
| WO2010124498A1 (en) | 2009-04-30 | 2010-11-04 | Beijing Cellonis Biotechnology Co., Ltd | A resistance-screened tumor stem cell, its antigen composition, an anti-tumor dendritic cell loading with said antigens, their preparation methods, uses and kits thereof as well as a dendritic cell vaccine |
| JP6066732B2 (ja) * | 2010-03-05 | 2017-01-25 | ザ・ジョンズ・ホプキンス・ユニバーシティー | 標的免疫調節抗体および融合タンパク質に基づく組成物および方法 |
| US8906374B2 (en) | 2010-04-20 | 2014-12-09 | Cedars-Sinai Medical Center | Combination therapy with CD4 lymphocyte depletion and mTOR inhibitors |
| WO2011139738A2 (en) * | 2010-04-28 | 2011-11-10 | Tenx Biopharma, Inc. | Therapies using zanolimumab to enhance the immune response |
| WO2013043647A1 (en) * | 2011-09-19 | 2013-03-28 | The Johns Hopkins University | Cancer immunotherapy |
| CN105979961B (zh) | 2014-02-05 | 2020-12-18 | 西达-赛奈医疗中心 | 用于治疗癌症和感染性疾病的方法和组合物 |
| AU2015264528A1 (en) * | 2014-05-21 | 2016-11-03 | Kyowa Hakko Kirin Co., Ltd. | Combination of an anti-CCR4 antibody and a 4-1BB agonist for treating cancer |
| WO2016088791A1 (ja) | 2014-12-02 | 2016-06-09 | 国立大学法人 東京大学 | 抗ｃｄ４抗体を有効成分とする抗がん剤の治療効果を判定する方法 |
-
2015
- 2015-02-05 CN CN201580007415.4A patent/CN105979961B/zh active Active
- 2015-02-05 EP EP15747022.0A patent/EP3102233B1/en active Active
- 2015-02-05 JP JP2016550261A patent/JP2017507931A/ja active Pending
- 2015-02-05 CA CA2937035A patent/CA2937035A1/en active Pending
- 2015-02-05 US US15/116,485 patent/US11213583B2/en active Active
- 2015-02-05 WO PCT/US2015/014687 patent/WO2015120198A1/en not_active Ceased
-
2020
- 2020-08-28 JP JP2020144077A patent/JP7328187B2/ja active Active
-
2021
- 2021-11-22 US US17/533,065 patent/US20220152198A1/en active Pending
-
2023
- 2023-08-03 JP JP2023126665A patent/JP7767361B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023133525A5 (enExample) | ||
| JP2017507931A5 (enExample) | ||
| JP2017501167A5 (enExample) | ||
| JP2017537090A5 (enExample) | ||
| JP2024156992A (ja) | 関節リウマチの治療 | |
| TWI877099B (zh) | 抗ｐｄ－１抗體或其抗原結合片段在製備治療用於患有肝細胞癌（ｈｃｃ）之藥物的用途 | |
| JP2017522307A5 (enExample) | ||
| CN106255510A (zh) | 使用抗pd‑1抗体与另一抗癌剂的组合治疗肾癌 | |
| JP2017537105A5 (enExample) | ||
| JP2019503387A5 (enExample) | ||
| JP2018512397A (ja) | 癌治療の有効性を高めるための組成物及び方法 | |
| JP2024513505A (ja) | 腫瘍を治療するための組成物及び方法 | |
| JP2021167324A5 (enExample) | ||
| JP2018515493A5 (enExample) | ||
| JP2019519584A5 (enExample) | ||
| CN112351795A (zh) | 采用抗癌药剂和以包含非典型hla-i及新抗原复合物为靶点的抗体的联合抗癌疗法 | |
| EP4536277A2 (en) | Combination therapy of anti-pd-1 active agent, anti-tim-3 active agent, and anti-lag-3 active agent for treating cancer | |
| WO2020243603A1 (en) | Dosing of bispecific t cell engager | |
| JPWO2019246356A5 (enExample) | ||
| WO2021178807A1 (en) | Combination of an lsd-1 inhibitor and nivolumab for use in treating sclc or sqnsclc | |
| US11684656B2 (en) | Combination therapy for malignant diseases | |
| JP7387912B2 (ja) | 免疫チェックポイント阻害剤抗体を使用した癌の処置のための方法及び組み合わせ | |
| JPWO2020160020A5 (enExample) | ||
| Stakiw et al. | A Phase II, Open-label study of an accelerated infusion rate of daratumumab in patients with relapsed and refractory multiple myeloma | |
| US20200148758A1 (en) | Therapeutic combinations comprising eosinophil-depleting antibodies and uses thereof |